European and North America venture capital firm Mérieux Equity Partners closed Mérieux Participations 3, a new investment fund dedicated to growth capital and buy-out within the Healthcare and Nutrition sectors, at € 377m.
Dedicated to supporting profitable and fast-growing companies in the healthcare and nutrition sectors, Mérieux Participations 3 fund was launched with the support of Institut Mérieux as a sponsor and an initial hard cap of € 350m. In December 2019, the new vehicle closed at € 377m, with commitments from European Family Holdings and Institutions.
As part of its development, Mérieux Equity Partners expanded its investment team in 2019 with the appointment of Marie-Justine Lecomte and Romain Chevrillon as Associates within the Growth Capital and Buy-Out team. The firm now employs 16 staff members in Lyon, Paris and Boston, of which 8 resources dedicated to Growth Capital & Buy-Out.
To date, Mérieux Participations 3 has completed seven transactions in France and Europe in support of fast-growing industrial companies, including four majority deals.
In 2019, Mérieux Equity Partners invested in:
- Addmedica – a French specialty pharmaceutical company engaged in rare diseases,
- Doc Generici – Italy’s largest independent generic pharmaceutical company – and
- Mabtech, a Swedish life science company specialized in immune monitoring.